ArticlePLoS neglected tropical diseases2014
Identification of differentially expressed proteins from Leishmania amazonensis associated with the loss of virulence of the parasites.
Article in PLoS neglected tropical diseases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Differentially modulated proteins associated with Leishmaniasis-a systematic review of in-vivo and in-vitro studies.Molecular biology reports · 2020Pooled it
- Comparison of a recombinant endonuclease III protein and its synthetic peptides in ELISA for the diagnosis of tegumentary leishmaniasis using human serum and urine samples: A preliminary study.PLoS neglected tropical diseases · 2026Article
- Circular RNAs: An Under-Recognized Part in Different Scenarios of Host-Parasite Interrelationships.Pathogens (Basel, Switzerland) · 2026Review
- Design of a novel multi epitope antigen for diagnosis of visceral leishmaniasis using an immunoinformatics approach.Scientific reports · 2025Article
- Distinct neutrophil effector functions in response to different isolates of Leishmania aethiopica.Parasites & vectors · 2024Article
- Molecular, structural, and functional characterization of delta subunit of T-complex protein-1 fromInfection and immunity · 2024Article
- Treatment of Refractory Mucosal Leishmaniasis Is Associated with Parasite Overexpression of HSP70 and ATPase and Reduced Host Hydrogen Peroxide Production (Brief Report).Biomedicines · 2024Article
- Extracellular Vesicles Released byMicroorganisms · 2023Article
- Immunoproteomics and phage display in the context of leishmaniasis complexity.Frontiers in immunology · 2023Review
- Development of an immunogen containing CD4Applied microbiology and biotechnology · 2022Article
- Screening Novel Vaccine Candidates forFrontiers in immunology · 2022Article
- Revisiting the Principles of Designing a Vaccine.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Potential therapeutic targets shared between leishmaniasis and cancer.Parasitology · 2021Review
- Long-TermJournal of immunology research · 2021Article
- Alkyl and Aryl Derivatives Based onMolecules (Basel, Switzerland) · 2020Article
- An immunoproteomic approach to identifying immunoreactive proteins inPathogens and global health · 2019Article
- Mapping Alterations Induced by Long-Term Axenic Cultivation ofFrontiers in cellular and infection microbiology · 2019Article
- Small Myristoylated Protein-3, Identified as a Potential Virulence Factor in Leishmania amazonensis, Proves to be a Protective Antigen against Visceral Leishmaniasis.International journal of molecular sciences · 2018Article
- Genome Plasticity in CulturedFrontiers in microbiology · 2018Article
- Identification of Leishmania donovani antigen in circulating immune complexes of visceral leishmaniasis subjects for diagnosis.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study analyzed whether or not the in vitro cultivation for long periods of time of pre-isolated Leishmania amazonensis from lesions of chronically infected BALB/c mice was able to interfere in the parasites' infectivity using in vivo and in vitro experiments. In addition, the proteins that presented a significant decrease or increase in their protein expression content were identified applying a proteomic approach. METHODOLOGY/PRINCIPAL
findingsParasites were cultured in vitro for 150 days. Aliquots were collected on the day 0 of culture (R0), as well as after ten (R10; 50 days of culture), twenty (R20; 100 days of culture), and thirty (R30; 150 days of culture) passages, and were used to analyze the parasites' in vitro and in vivo infectivity, as well as to perform the proteomic approach. Approximately 837, 967, 935, and 872 spots were found in 2-DE gels prepared from R0, R10, R20, and R30 samples, respectively. A total of 37 spots presented a significant decrease in their intensity of expression, whereas a significant increase in protein content during cultivation could be observed for 19 proteins (both cases >2.0 folds). Some of these identified proteins can be described, such as diagnosis and/or vaccine candidates, while others are involved in the infectivity of Leishmania. It is interesting to note that six proteins, considered hypothetical in Leishmania, showed a significant decrease in their expression and were also identified. CONCLUSIONS/SIGNIFICANCE: The present study contributes to the understanding that the cultivation of parasites over long periods of time may well be related to the possible loss of infectivity of L. amazonensis. The identified proteins that presented a significant decrease in their expression during cultivation, including the hypothetical, may also be related to this loss of parasites' infectivity, and applied in future studies, including vaccine candidates and/or immunotherapeutic targets against leishmaniasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.